Literature DB >> 15958034

Future of home haemodialysis in Australia and New Zealand.

Kelvin L Lynn1, Adrian L Buttimore.   

Abstract

Maintenance haemodialysis (HD) was pioneered in Seattle and rapidly became home-based. When dialysis treatment began in Australia and New Zealand, home haemodialysis (HHD) became the predominant form of dialysis. When compared with in-centre conventional dialysis, HHD is associated with superior survival and quality of life and is cheaper. There is currently significant interest in increasing the frequency and duration of dialysis and in providing more flexible dialysis regimens for patients. If the likely benefits of these treatment changes are to be fully realized HHD and self care HD services will need to expand. Dialysis units in Australia and New Zealand are better equipped than most to respond to this challenge.

Entities:  

Mesh:

Year:  2005        PMID: 15958034     DOI: 10.1111/j.1440-1797.2005.00399.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  4 in total

1.  The organization and financing of dialysis and kidney transplantation services in New Zealand.

Authors:  Toni Ashton; Mark Roger Marshall
Journal:  Int J Health Care Finance Econ       Date:  2007-12

2.  Exsanguination of a home hemodialysis patient as a result of misconnected blood-lines during the wash back procedure: a case report.

Authors:  Kerryanne Allcock; Balaji Jagannathan; Christopher J Hood; Mark R Marshall
Journal:  BMC Nephrol       Date:  2012-05-15       Impact factor: 2.388

3.  Clinician beliefs and attitudes about home haemodialysis: a multinational interview study.

Authors:  Allison Tong; Suetonia Palmer; Braden Manns; Jonathan C Craig; Marinella Ruospo; Letizia Gargano; David W Johnson; Jörgen Hegbrant; Måns Olsson; Steven Fishbane; Giovanni F M Strippoli
Journal:  BMJ Open       Date:  2012-12-12       Impact factor: 2.692

4.  Survival on home dialysis in New Zealand.

Authors:  Mark R Marshall; Rachael C Walker; Kevan R Polkinghorne; Kelvin L Lynn
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.